🌍·17h agoIndustry
Journal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trial
Publisher
B
Bicara Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bicara.com
Leave the platform to read the original full article on the publisher site.
Source: Bicara Therapeutics
Scope: Industry
Related coverage
More related coverage
Natco Pharma·15h ago
natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26
Natco Pharma·15h ago
natco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26
Natco Pharma·15h ago
natco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fda
Natco Pharma·15h ago